Antibody Information
General Information of This Antibody
| Antibody ID | ANI0VZIZQ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Intetumumab |
|||||
| Synonyms |
IMGN-388 mAb
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG |
|||||
| Antigen Name | Integrin alpha-V (ITGAV) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYY
VDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS Click to Show/Hide
|
|||||
| Light Chain Sequence |
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPA
RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
IMGN388 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Advanced solid tumors.
|
||||
| Administration Dosage |
Doses ranging from 5 to 80 mg/m2, every 3 weeks, IV.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00721669 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
|
||||
| Primary Endpoint |
No evidence of activity was observed at the lowest doses (45 mg/m2) evaluated.
|
||||
| Other Endpoint |
No evidence of human anti-human antibody formation (data available for doses up to 60 mg/m2.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT00721669 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
|
||||
| Primary Endpoint |
Five patients (breast,prostate,neuroendocrine,and 2 NSCLC) treated at doses 45 mg/m2 have acheived stable disease for 4 cycles.
|
||||
References